Shandong Lukang Pharmaceutical Co Ltd

Shandong Lukang Pharmaceutical Co Ltd – also known as Lukang Pharma - was established in 1966 in Jining, East China's Shandong province. It is a State-owned large-scale pharmaceuticals enterprise, which was listed on the main share market board of the Shanghai Stock Exchange in 1997. (Stock abbreviation: Lukang Pharma; stock number: 600789).

To date, the company has reported total assets of 6.6 billion yuan ($1.03 billion) and more than 6,000 employees. The company owns 13 joint ownership enterprises, including five wholly owned subsidiaries, six holding companies and two joint ventures.

Qinghai Lukang Dadi Company is its production operation for traditional Chinese medicine and traditional Tibetan medicine. Shandong Lukang Saite Company is its manufacturer for non-penicillin and non-cephalosporin FDFs (FDFs, also known as finished dosage form products, are actual finalized drug products that are meant for consumption) and Shandong Lukang Biological Pesticides Company makes agricultural chemicals.

Lukang Pharma specializes in manufacturing APIs (active pharmaceutical ingredients) for both human and veterinary use, as well as FDFs for human use and agricultural chemicals. It supplies a total of over 500 types of products, such as anti-infective, cardiovascular and cerebrovascular drugs, diabetes drugs and amino acids products.

The company has an annual production capacity of 150,000 tons of various kinds of APIs, six billion tablets/capsules/bags of oral solid FDFs and two billion vials of powder for injection.

The company has passed ISO 9001, ISO 14001, and OHMS quality certifications. Several products have passed US Federal Drug Administration inspection or have been given CEP certificates (certificates of suitability to monograph of European) and one product has received European Union certification. Lukang Pharma sells its products well across the country and exports to 50 countries and regions across Asia, Europe, Africa and America - with $150 million of annual exports.

At present, Lukang Pharma has four national high-tech enterprises, one State-level enterprise technology center, two provincial enterprise technology center, one Shandong province engineering technology research center and has established an academician workstation and post-doctoral scientific research workstation.

Lukang Pharma has been conferred with the title of "National Torch Plan Key High-tech Enterprise" and was among the first group to officially be designated as a "National Comprehensive New Drug Research and Development Technology Platform (Shandong) Industrialization Demonstration Enterprise".

In 2017, Lukang Pharma established the Shandong Provincial Biotechnology Industry Transform Platform together with the Tianjin Institute of Chinese Academy of Sciences.

The following year, the Shandong brand international science and technology cooperation base was approved by the Department of Science and Technology of Shandong Province and the Shandong University-Lukang Institute of Pharmaceutical Microbiology was established.